Acro Biomedical Co Stock Current Valuation
| ACBM Stock | USD 0 0.00 0.00% |
Valuation analysis of ACRO Biomedical helps investors to measure ACRO Biomedical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that ACRO Biomedical's price fluctuation is very steady at this time. Calculation of the real value of ACRO Biomedical is based on 3 months time horizon. Increasing ACRO Biomedical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ACRO pink sheet is determined by what a typical buyer is willing to pay for full or partial control of ACRO Biomedical Co. Since ACRO Biomedical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ACRO Pink Sheet. However, ACRO Biomedical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.001 | Real 8.4E-4 | Hype 0.001 | Naive 0.001 |
The intrinsic value of ACRO Biomedical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ACRO Biomedical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ACRO Biomedical Co helps investors to forecast how ACRO pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ACRO Biomedical more accurately as focusing exclusively on ACRO Biomedical's fundamentals will not take into account other important factors: ACRO Biomedical Co Company Current Valuation Analysis
ACRO Biomedical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ACRO Biomedical Current Valuation | 240.18 M |
Most of ACRO Biomedical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ACRO Biomedical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ACRO Biomedical Co has a Current Valuation of 240.18 M. This is 98.33% lower than that of the Healthcare sector and 94.83% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 98.56% higher than that of the company.
ACRO Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ACRO Biomedical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ACRO Biomedical could also be used in its relative valuation, which is a method of valuing ACRO Biomedical by comparing valuation metrics of similar companies.ACRO Biomedical is currently under evaluation in current valuation category among its peers.
ACRO Fundamentals
| Return On Equity | -29.78 | |||
| Return On Asset | -15.5 | |||
| Operating Margin | (17.61) % | |||
| Current Valuation | 240.18 M | |||
| Shares Outstanding | 60.04 M | |||
| Shares Owned By Insiders | 49.97 % | |||
| Price To Book | 487.98 X | |||
| Price To Sales | 267.90 X | |||
| Revenue | 1.2 M | |||
| Gross Profit | 259.5 K | |||
| EBITDA | (7.69 M) | |||
| Net Income | 7.7 M | |||
| Cash And Equivalents | 12.11 K | |||
| Total Debt | 59.44 K | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 7.70 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 299.33 K | |||
| Earnings Per Share | (0.20) X | |||
| Beta | 0.92 | |||
| Market Capitalization | 209.55 M | |||
| Total Asset | 761.08 K | |||
| Net Asset | 761.08 K |
About ACRO Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ACRO Biomedical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACRO Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACRO Biomedical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in ACRO Pink Sheet
ACRO Biomedical financial ratios help investors to determine whether ACRO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ACRO with respect to the benefits of owning ACRO Biomedical security.